[
    [
        {
            "time": "",
            "original_text": "【浙商医药|周报】第三批集采方案下发，持续看好API板块成长性",
            "features": {
                "keywords": [
                    "第三批集采",
                    "方案下发",
                    "API板块",
                    "成长性"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "API"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【浙商医药|周报】第三批集采方案下发，持续看好API板块成长性",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "泰格医药孖展912亿元 超额认购约154倍",
            "features": {
                "keywords": [
                    "泰格医药",
                    "孖展",
                    "超额认购",
                    "154倍"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "泰格医药孖展912亿元 超额认购约154倍",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "港股IPO动态：泰格医药(3347.HK)和智勤控股(9913.HK)目前处于申购期",
            "features": {
                "keywords": [
                    "港股IPO",
                    "泰格医药",
                    "智勤控股",
                    "申购期"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "港股IPO动态：泰格医药(3347.HK)和智勤控股(9913.HK)目前处于申购期",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]